Video

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Author(s):

Michael A. Morse, MD,Nicole Rich, MD

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
FDA
November 21st 2024

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Tanios S. Bekaii-Saab, MD
November 19th 2024

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tanios S. Bekaii-Saab, MD
November 17th 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

Sebastian Kaulitzki – stock.adobe.com
November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More